DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Stage IV Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 250

Registration Number: NCT00146549

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

Phase 2

Completed

Conditions: Hematologic Malignancies
Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Hodgkin's Disease

First Posted Date: 2005-09-05

Last Posted Date: 2012-01-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT00144703

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Graft Versus Host Disease
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Non-Hodgkin's Lymphoma
Hodgkin's Disease

First Posted Date: 2005-09-05

Last Posted Date: 2012-01-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00144677

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Lymphoplasmacytic Lymphoma
Waldenstrom's Macroglobulinemia

Interventions: Drug: Campath-1H

First Posted Date: 2005-09-02

Last Posted Date: 2012-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00142181

Locations: 🇺🇸
Beth Isreal Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-farber Cancer Insitiute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

Not Applicable

Completed

Conditions: Waldenstrom's Macroglobulinemia

First Posted Date: 2005-09-02

Last Posted Date: 2011-06-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 300

Registration Number: NCT00142155

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia
Lymphoplasmacytic Lymphoma

First Posted Date: 2005-09-02

Last Posted Date: 2011-06-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00142129

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: CC-5103 (lenalidomide)
Drug: Rituximab

First Posted Date: 2005-09-02

Last Posted Date: 2016-04-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00142168

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Preventing Adverse Drug Events With PatientSite

Not Applicable

Completed

Conditions: Adverse Drug Event

Interventions: Other: Medcheck message

First Posted Date: 2005-09-01

Last Posted Date: 2013-02-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 800

Registration Number: NCT00140504

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Adenocarcinoma of Prostate

First Posted Date: 2005-09-01

Last Posted Date: 2009-12-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00140478

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients

Not Applicable

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-08-31

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00139204

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy